Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
暂无分享,去创建一个
A. Moser | H. Zeh | D. Bartlett | B. Lembersky | N. Bahary | Kenneth K. Lee | S. Hughes | P. Bao | R. Ramanathan | A. J. Moser | A. Krasinkas | Herbert Zeh | Alyssa M. Krasinkas
[1] Edward S. Kim,et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Dacic,et al. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas , 2010, Modern Pathology.
[3] T. Gauler,et al. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ , 2010, Anti-cancer drugs.
[4] A. Moser,et al. Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. , 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[5] J. Neoptolemos,et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin , 2009, Histopathology.
[6] H. Ueno,et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer , 2009, British Journal of Cancer.
[7] P. Catalano,et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Noone,et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. , 2009, Gastrointestinal cancer research : GCR.
[9] D. Smith,et al. ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] B. Topal,et al. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[11] M. Büchler,et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials , 2009, British Journal of Cancer.
[12] Lesley Seymour,et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] K. Trinkaus,et al. Adjuvant Interferon-based Chemoradiation Followed By Gemcitabine for Resected Pancreatic Adenocarcinoma: A Single-Institution Phase II Study , 2008, Annals of surgery.
[14] R. Abrams,et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. , 2008, JAMA.
[15] Jeffrey E. Lee,et al. Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma , 2007, Annals of surgery.
[16] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Roy S Herbst,et al. KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.
[18] Peter Neuhaus,et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.
[19] Michael A. Choti,et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience , 2006, Journal of Gastrointestinal Surgery.
[20] Helen Hickey,et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.
[21] J. Hainsworth,et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Fjällskog,et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] Carlos L Arteaga,et al. ErbB-targeted therapeutic approaches in human cancer. , 2003, Experimental cell research.
[24] J. Abbruzzese,et al. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. , 2002, Seminars in oncology.
[25] I Ihse,et al. Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial , 2001, Annals of surgery.
[26] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[27] J. Jeekel,et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. , 1999, Annals of surgery.
[28] Zhong Wen-zhao,et al. Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome , 2006 .